OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.
Objective: To define the nomenclature for Early Onset Parkinson Disease (EOPD) / Young Onset Parkinson Disease (YOPD), and the age at onset (AAO) cut off…A lower rate of hyposmia in non-Ashkenazi jewish patients with Parkinson’s disease: motor and non-motor disease characteristics in different ethnic groups in Israel
Objective: We aim to describe clinical aspects of Parkinson's disease (PD) in different ethnic groups in Israel, focusing on Non-Ashkenzi Jews (NAJ) ethnic groups vs.…Parkinson’s disease caregiver burden in rural India
Objective: To assess the caregiver burden and factors determining it in patients with PD. To assess the anxiety and depression amongst caregivers. Background: Patients with…PD+: A comprehensive, user-friendly mobile application for clinicians treating Parkinson’s Disease
Objective: We developed a mobile application that converts dopaminergic medication dosages and calculates total Levodopa (L-dopa) equivalent daily dose (LEDD) in a Parkinson’s Disease (PD)…Visual system abnormalities and visual hallucinations in Parkinson’s disease
Objective: We aimed to identify clinical and imaging biomarkers of visual system injury associated with the presence of Visual hallucinations (VH) in Parkinson's disease (PD).…Alterations in neuron-derived exosomal cargo in Parkinson Disease
Objective: The main objectives are 1) the confirmation of exosome isolation, based on iPSC-derived midbrain neuron model, 2) the identification of α-synuclein cargo of PD-patient…Type 2 diabetes-associated transcriptomic changes in Parkinson’s disease and non-neurodegenerative control brains.
Objective: To evaluate the effect of type 2 diabetes (T2D) on gene transcription in Parkinson’s disease (PD) and non-neurodegenerative control brains. Background: People with T2D…Neurophysiological and Clinical Effects of Low-intensity Transcranial Ultrasound of the Motor Cortex in Parkinson’s Disease
Objective: Evaluate the neurophysiological and clinical effects of transcranial ultrasound stimulation (TUS) of motor cortex (M1) in PD patients. Background: Low-intensity TUS is a novel,…Validity and reliability of the Thai version of the Freezing of Gait Questionnaire (FOG-Q) in individuals with Parkinson’s disease (PD)
Objective: To evaluate the validity and reliability of the Thai version of FOG-Q (Thai FOG-Q) in individuals with PD. Background: Freezing of gait (FOG) is…
- « Previous Page
- 1
- …
- 215
- 216
- 217
- 218
- 219
- …
- 338
- Next Page »